Filing summary
Issuer discrepancy: Although the request identifies CYPHERPUNK TECHNOLOGIES INC., the supplied Form 10-Q is for Leap Therapeutics, Inc. It covers the quarter ended June 30, 2017, and was signed August 11, 2017. The summary below reflects the filing provided.
Business context and reporting period
Leap is a clinical-stage biopharmaceutical company developing DKN-01 and TRX518, investigational cancer therapies. It had no approved products and generated no product-sales revenue. The filing states the candidates had not been submitted to the FDA for approval. Results cover the three and six months ended June 30, 2017, compared with the same periods in 2016.
Financial performance and position
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Revenue from product sales | None | None | None | None |
| Research and development expense | $4.881m | $6.124m | $11.285m | $10.211m |
| General and administrative expense | $2.135m | $1.070m | $5.939m | $2.126m |
| Net loss | $6.905m | $7.477m | $16.319m | $12.624m |
| Net loss per share | $(0.74) | Not presented | $(2.03) | Not presented |
All financial amounts above are in U.S. dollars. No meaningful revenue or gross margin was reported because the company had no product sales. Operating expenses were $7.016m in Q2 2017 and $17.224m for the first half. Australian R&D incentive income was $0.494m in Q2 and $0.891m for the first half; Q2 also included a $0.432m foreign-currency loss.
At June 30, 2017, cash and cash equivalents were $17.171m; current assets were $20.723m and current liabilities $4.375m. Total assets were $22.726m and stockholders’ equity $18.351m. The balance sheet showed no remaining related-party notes payable: $31.145m of principal and accrued interest had converted into common shares in January. The company reported a $116.989m accumulated deficit.
For the first half, operating cash use was $13.411m, investing cash use $0.066m, and financing cash provided $29.868m, resulting in a $16.378m increase in cash. Financing included $21.165m from the Macrocure merger-related share issuance, $10.000m from a common-stock sale, and $0.750m of related-party note proceeds, partly offset by $2.067m of deferred offering-cost payments. Q2 cash declined by $6.629m, according to the liquidity disclosure.
Material changes and notable transactions
- Q2 net loss improved by $0.572m year over year, with lower R&D expense and no related-party interest expense, partly offset by higher G&A and foreign-currency losses. For the first half, net loss widened by $3.695m, primarily alongside increased G&A and R&D expenses.
- R&D expense shifted between programs: Q2 DKN-01 expense declined to $2.693m from $5.118m, while TRX518 expense rose to $2.188m from $1.006m. First-half R&D expense increased overall, including higher clinical-trial and stock-based compensation costs.
- The January 2017 merger with Macrocure was accounted for as an in-substance recapitalization. The company’s preferred stock and related-party notes converted into common shares; Macrocure shareholders received 3,256,898 shares. Common-stock trading began on Nasdaq under LPTX in January.
- Stock-based compensation was $4.256m for the first half versus $0.018m a year earlier. The merger also led to $0.280m of accelerated compensation expense and a $0.504m charge for extending option exercise periods.
- A royalty agreement provides a special-purpose vehicle with 5% of net sales of products incorporating TRX518 and 2% for DKN-01, if such sales occur. The agreement has an indefinite term and neither party may terminate it.
Outlook, risks, and contingencies
Management expects operating losses and expenses to continue and says R&D and public-company costs are expected to increase. It did not provide a specific earnings, revenue, or cash-runway forecast. Management identified substantial doubt about the company’s ability to continue as a going concern for one year after issuance of the financial statements, citing funding needs and uncertainty about obtaining additional capital. It expected approximately $3.2m of Australian R&D incentive payments in 2017 and planned to pursue equity financing, government programs, collaborations, or licenses. Without additional funding or cost-sharing, it could delay, reduce, or eliminate trials and R&D programs.
Clinical and business updates included a Merck collaboration and supply agreement to study DKN-01 with KEYTRUDA in esophagogastric cancer; preliminary median progression-free survival of 9.4 months in a DKN-01 biliary tract cancer trial; completed enrollment of an expanded cohort in that study; and completion of dose escalation and enrollment of the expansion cohort in a TRX518 study. These are development updates, not evidence of regulatory approval or assured clinical benefit.
Risks include clinical-trial outcomes and timing, regulatory requirements, competition, manufacturing and financing needs, and potential dilution or unfavorable collaboration terms. The company disclosed European patent opposition proceedings involving TRX518 patents. Noncancelable manufacturing commitments for DKN-01 and TRX518 totaled $3.793m at June 30. Potential low-single-digit royalties to Lilly and Lonza may apply to future product sales; none had been paid or accrued. The filing also notes that future indemnification obligations could be unlimited in some cases, though no related liability was accrued.
Important facts for investors to verify
- Confirm the issuer: the provided filing is Leap Therapeutics, Inc., not Cypherpunk Technologies Inc.
- Review the going-concern warning, available cash, expected incentive receipts, and the timing and terms of any subsequent financing.
- Check the underlying clinical data and trial status for DKN-01 and TRX518, including the preliminary 9.4-month median progression-free survival result.
- Assess the potential effect of the 5% TRX518 and 2% DKN-01 royalty obligations, as well as license royalties and manufacturing commitments.
- Consider dilution and compensation costs: the filing reports substantial stock-based compensation and 1,863,722 options outstanding at June 30, 2017.